. 2025 Mar 19:50:126818.

doi: 10.1016/j.vaccine.2025.126818. Epub 2025 Feb 6.

Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada

E McClymont¹, J M H Wong¹, L Forward¹, S Blitz¹, J Barrett², T Bogler³, I Boucoiran⁴, E Castillo⁵, R D'Souza⁶, D El-Chaâr⁷, S A Fadel⁸, S Gantt⁹, V Kuret⁵, G Ogilvie¹⁰, V Poliquin¹¹, M Sadarangani¹², H Scott¹³, J W Snelgrove¹⁴, M Tunde-Byass¹⁴, D Money¹⁵; COVERED Team

Collaborators, Affiliations

Collaborators

COVERED Team:
Rashid Ahmed¹⁶, Julie Bettinger¹⁷, Kathryn Bocking¹⁸, Lori Brotto¹⁷, George Carson¹⁹, Krista Cassell²⁰, Joan Crane²¹, Chelsea Elwood¹⁷, Fatima Kakkar²², Eda Karacabeyli¹⁷, Ann Kinga Malinowski²³, Sarah Saunders²⁴, Tatiana Sotindjo¹⁷

Affiliations

¹ Department of Obstetrics & Gynecology, University of British Columbia, Vancouver, Canada.
² Department of Obstetrics & Gynecology, McMaster University, Hamilton, Canada.
³ Department of Family & Community Medicine, University of Toronto, Toronto, Canada.
⁴ Department of Obstetrics & Gynecology and School of Public Health, Université de Montréal, Montreal, Canada; CHU Sainte-Justine Research Center, Montreal, Canada.
⁵ Departments of Medicine and of Obstetrics & Gynecology, University of Calgary, Calgary, Canada.
⁶ Department of Obstetrics & Gynecology, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.
⁷ Department of Obstetrics & Gynecology, University of Ottawa, Ottawa, Canada.
⁸ Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
⁹ CHU Sainte-Justine Research Center, Montreal, Canada; Department of Pediatrics, Université de Montréal, Montreal, Canada.
¹⁰ School of Population & Public Health, University of British Columbia, Vancouver, Canada.
¹¹ Department of Obstetrics, Gynecology, & Reproductive Sciences, University of Manitoba, Winnipeg, Canada.
¹² Vaccine Evaluation Center, BC Children 's Hospital Research Institute, Vancouver, Canada; Department of Pediatrics, University of British Columbia, Vancouver, Canada.
¹³ Department of Obstetrics & Gynecology, Dalhousie University, Halifax, Canada.
¹⁴ Department of Obstetrics & Gynaecology, University of Toronto, Toronto, Canada.
¹⁵ Department of Obstetrics & Gynecology, University of British Columbia, Vancouver, Canada; Women's Health Research Institute, Vancouver, Canada. Electronic address: deborah.money@ubc.ca.
¹⁶ McMaster University.
¹⁷ University of British Columbia.
¹⁸ NB Perinatal Health Program.
¹⁹ University of Saskatchewan.
²⁰ Queen Elizabeth Hospital.
²¹ Memorial University of Newfoundland.
²² Université de Montréal.
²³ University of Toronto.
²⁴ Whitehorse General Hospital.

PMID: 39919449
DOI: 10.1016/j.vaccine.2025.126818

Free article

Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada

E McClymont et al. Vaccine. 2025.

Free article

. 2025 Mar 19:50:126818.

doi: 10.1016/j.vaccine.2025.126818. Epub 2025 Feb 6.

Authors

Collaborators

COVERED Team:
Rashid Ahmed¹⁶, Julie Bettinger¹⁷, Kathryn Bocking¹⁸, Lori Brotto¹⁷, George Carson¹⁹, Krista Cassell²⁰, Joan Crane²¹, Chelsea Elwood¹⁷, Fatima Kakkar²², Eda Karacabeyli¹⁷, Ann Kinga Malinowski²³, Sarah Saunders²⁴, Tatiana Sotindjo¹⁷

Affiliations

¹ Department of Obstetrics & Gynecology, University of British Columbia, Vancouver, Canada.
² Department of Obstetrics & Gynecology, McMaster University, Hamilton, Canada.
³ Department of Family & Community Medicine, University of Toronto, Toronto, Canada.
⁴ Department of Obstetrics & Gynecology and School of Public Health, Université de Montréal, Montreal, Canada; CHU Sainte-Justine Research Center, Montreal, Canada.
⁵ Departments of Medicine and of Obstetrics & Gynecology, University of Calgary, Calgary, Canada.
⁶ Department of Obstetrics & Gynecology, McMaster University, Hamilton, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada.
⁷ Department of Obstetrics & Gynecology, University of Ottawa, Ottawa, Canada.
⁸ Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
⁹ CHU Sainte-Justine Research Center, Montreal, Canada; Department of Pediatrics, Université de Montréal, Montreal, Canada.
¹⁰ School of Population & Public Health, University of British Columbia, Vancouver, Canada.
¹¹ Department of Obstetrics, Gynecology, & Reproductive Sciences, University of Manitoba, Winnipeg, Canada.
¹² Vaccine Evaluation Center, BC Children 's Hospital Research Institute, Vancouver, Canada; Department of Pediatrics, University of British Columbia, Vancouver, Canada.
¹³ Department of Obstetrics & Gynecology, Dalhousie University, Halifax, Canada.
¹⁴ Department of Obstetrics & Gynaecology, University of Toronto, Toronto, Canada.
¹⁵ Department of Obstetrics & Gynecology, University of British Columbia, Vancouver, Canada; Women's Health Research Institute, Vancouver, Canada. Electronic address: deborah.money@ubc.ca.
¹⁶ McMaster University.
¹⁷ University of British Columbia.
¹⁸ NB Perinatal Health Program.
¹⁹ University of Saskatchewan.
²⁰ Queen Elizabeth Hospital.
²¹ Memorial University of Newfoundland.
²² Université de Montréal.
²³ University of Toronto.
²⁴ Whitehorse General Hospital.

PMID: 39919449
DOI: 10.1016/j.vaccine.2025.126818

Abstract

Background: Vaccination during pregnancy and infant monoclonal antibodies (mAb) were recently approved to prevent respiratory syncytial virus (RSV) disease in infants. Our study aims to describe self-reported attitudes and preferences between vaccination during pregnancy and infant mAb for this indication.

Methods: From September 2023-March 2024, we completed a web-based, cross-sectional survey within the COVERED national prospective cohort study. Individuals who became pregnant in 2023 and were ≥ 19 years of age were included. We assessed demographics and general vaccination attitudes within and outside pregnancy, as well as attitudes toward newly licensed RSV products (i.e., vaccine during pregnancy, infant mAb), that were not yet available. Univariate and multivariate analysis was completed to identify predictors of accepting RSV immunization during pregnancy.

Results: A total of 723 participants completed the RSV survey module, of which 50.3 % (n = 364) were currently pregnant. Among all participants, 79 % (n = 568) would accept at least one of the RSV immunization strategies; 77 % (n = 559) would accept RSV vaccination during pregnancy and 55 % (n = 396) would accept infant mAb. Vaccination during pregnancy was preferred by 79 % (n = 567) of participants, infant mAb were preferred by 4.4 % (n = 32), and 14 % (n = 98) indicated no preference. Participants rated Tdap vaccination as the highest priority (51 %) followed by RSV (17 %), COVID-19 (14 %), hepatitis B (11 %), and influenza (7 %). Predictors of accepting RSV vaccine during pregnancy included acceptance of Tdap and COVID-19 vaccines during pregnancy (p < 0.001 and p = 0.006, respectively) and ranking RSV as a high priority among pregnancy vaccines (p = 0.006).

Conclusion: In this national survey, more than two thirds of participants would accept the RSV vaccine while more than half would accept mAb. If given a choice, the vast majority preferred vaccination during pregnancy over mAb. These preferences should be considered when drafting policies and could influence cost-utility analyses.

Keywords: Infant immunization; Monoclonal antibody; Pregnancy; Respiratory Syncytial Virus; Respiratory Syncytial Virus Vaccines.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Deborah Money reports financial support was provided by Public Health Agency of Canada. Elisabeth McClymont reports a relationship with Michael Smith Foundation for Health Research that includes: funding grants. Elisabeth McClymont reports a relationship with Canadian Institutes of Health Research Canadian HIV Trials Network/Canadian Association for AIDS Research that includes: funding grants. Jeffrey MH Wong reports a relationship with ViiV Healthcare that includes: funding grants. Jeffrey MH Wong reports a relationship with Canadian Institutes of Health Research Canadian HIV Trials Network that includes: funding grants. Jon Barrett reports a relationship with Ferring Pharmaceuticals Inc. that includes: funding grants. Jon Barrett reports a relationship with Myant Inc. that includes: consulting or advisory. Isabelle Boucoiran reports a relationship with Quebec Health Research Fund that includes: funding grants. Isabelle Boucoiran reports a relationship with Pfizer that includes: funding grants. Isabelle Boucoiran reports a relationship with GSK that includes: funding grants. Rohan D'Souza reports a relationship with Tier-2 Canada Research Chair in Maternal Mental Health (CRC-2021-00337) that includes: funding grants. Darine El-Chaâr reports a relationship with Moderna Inc. that includes: funding grants. Shaza A Fadel reports a relationship with Merck & Co Inc. that includes: funding grants. Soren Gantt reports a relationship with Moderna Inc. that includes: consulting or advisory and funding grants. Soren Gantt reports a relationship with Merck & Co Inc. that includes: consulting or advisory and funding grants. Soren Gantt reports a relationship with GSK that includes: consulting or advisory and funding grants. Soren Gantt reports a relationship with Curevo Vaccine that includes: consulting or advisory. Soren Gantt reports a relationship with Pfizer that includes: funding grants. Soren Gantt reports a relationship with Altona Diagnostics that includes: funding grants. Vanessa Poliquin reports a relationship with Sanofi Pasteur Inc. that includes: speaking and lecture fees. Manish Sadarangani reports a relationship with BC Children's Hospital Foundation that includes: funding grants. Manish Sadarangani reports a relationship with Michael Smith Health Research BC that includes: funding grants. Manish Sadarangani reports a relationship with GlaxoSmithKline Inc. that includes: funding grants. Manish Sadarangani reports a relationship with Merck & Co Inc. that includes: funding grants. Manish Sadarangani reports a relationship with Moderna Inc. that includes: funding grants. Manish Sadarangani reports a relationship with Pfizer that includes: funding grants. Manish Sadarangani reports a relationship with Sanofi Pasteur Inc. that includes: funding grants. Modupe Tunde-Byass reports a relationship with Ferring Pharmaceuticals Inc. that includes: funding grants and speaking and lecture fees. Deborah Money reports a relationship with Merck & Co Inc. that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada

Collaborators

Affiliations

Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical